Costantino Del Giudice

Costantino Del Giudice

Auto-generated profile, based on publicly available information

Costantino Del Giudice

Department of Radiology, Interventional Radiology, Institut Mutualiste Montsouris, Paris, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
RPRuggero De Paulis
Ruggero De Paulis
SNStefano de Notaris
Stefano de Notaris
RSRaffaele Scaffa
Raffaele Scaffa
SNSaverio Nardella
Saverio Nardella
JZJacob ZEITANI
Jacob ZEITANI
LCLuigi Chiariello
Luigi Chiariello

1 December 2013 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
RGRoberto Gandini
Roberto Gandini
CGCostantino Del Giudice
Costantino Del Giudice
SMStefano Merolla
Stefano Merolla
DMDaniele Morosetti
Daniele Morosetti
EPEnrico Pampana
Enrico Pampana
GSGiovanni Simonetti
Giovanni Simonetti
To compare the safety and efficacy of laser debulking (LD) and drug-eluting balloon (DEB) angioplasty to treatment with DEB angioplasty alone in patients affected by critical limb ischemia (CLI) and superficial femoral artery (SFA) chronic stent occlusion in a prospective, randomized study. Among 448 CLI patients treated from December 2009 to March 2011, 48 patients (39 men; mean age 72.7±7.8 years) with chronic SFA in-stent occlusion were randomly assigned to treatment using LD+DEB (n=24) or DEB angioplasty alone (n=24). Patency at 12 months was the primary outcome measure; secondary outcomes were target lesion revascularization (TLR) and clinical success at 12 months. In the LD+DEB group, the patency rates at 6 and 12 months (91.7% and 66.7%, respectively) were significantly higher (p=0.01) than in the DEB only patients (58.3% and 37.5%, respectively). TLR at 12 months was 16.7% in the LD+DEB group and 50% in the DEB only group (p=0.01). Two (8%) patients needed major amputations in the LD+DEB group vs. 11 (46%) in the DEB only group at 12 months (p=0.003). In this small initial experience, combined treatment with LD and DEB angioplasty is correlated with better outcomes in CLI patients with occluded SFA stents.

1 May 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
SSSabine Steiner
Sabine Steiner
AWAndrea Willfort-Ehringer
Andrea Willfort-Ehringer
HSHorst Sievert
Horst Sievert
VGVolker Geist
Volker Geist
MLMichael Lichtenberg
Michael Lichtenberg
DSDierk Scheinert
Dierk Scheinert
The authors sought to evaluate the performance of the Ranger paclitaxel-coated balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months. Drug-coated balloons (DCBs) are a promising endovascular treatment option for peripheral artery disease of the femoropopliteal segment, and each unique device requires dedicated clinical study. The prospective, randomized RANGER SFA (Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries) study (NCT02013193) enrolled 105 patients with symptomatic lower limb ischemia (Rutherford category 2 to 4) and stenotic lesions in the nonstented femoropopliteal segment at 10 European centers. Seventy-one patients (mean age 68 ± 8 years, n = 53 men) were enrolled in the Ranger DCB arm, and 34 patients (mean age 67 ± 9 years, n = 23 men) were assigned to the control group. Twelve-month analysis included patency, safety, and clinical outcomes and quality-of-life assessments. The DCB group had a greater primary patency rate at 12 months (Kaplan-Meier estimate 86.4% vs. 56.5%), with a significantly longer time to patency failure (log-rank p < 0.001). The estimated freedom from target lesion revascularization rate was 91.2% in the DCB group and 69.9% in the control group at 12 months, with a significantly longer time to reintervention (p = 0.010). No target limb amputations or device-related deaths occurred in either group. Twelve-month results show that patency was maintained longer after Ranger DCB treatment than after conventional balloon angioplasty, and this result was associated with a low revascularization rate and good clinical outcomes.

1 January 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
KKKonstantinos Katsanos
Konstantinos Katsanos
SSStavros Spiliopoulos
Stavros Spiliopoulos
UTUlf Teichgräber
Ulf Teichgräber
PKPanagiotis Kitrou
Panagiotis Kitrou
CGCostantino Del Giudice
Costantino Del Giudice
DKDimitrios Karnabatidis
Dimitrios Karnabatidis
There have been concerns about the long term safety of paclitaxel coated devices in the lower limbs. A formal systematic review and meta-analysis of randomised controlled trials (RCTs) was performed to examine the long term risk of major amputation using paclitaxel coated balloons in peripheral arterial disease (PAD). This systematic review was registered with PROSPERO (ID 227761). A broad bibliographic search was performed for RCTs investigating paclitaxel coated balloons in the peripheral arteries (femoropopliteal and infrapopliteal) for treatment of intermittent claudication or critical limb ischaemia (CLI). The literature search was last updated on 20 February 2021 without any restrictions on publication language, date, or status. Major amputations were analysed with time to event methods employing one and two stage models. Sensitivity and subgroup analyses, combinatorial meta-analysis, and a multivariable dose response meta-analysis to examine presence of a biological gradient were also performed. In all, 21 RCTs with 3 760 lower limbs were analysed (52% intermittent claudication and 48% CLI; median follow up two years). There were 87 major amputations of 2 216 limbs in the paclitaxel arms (4.0% crude risk) compared with 41 major amputations in 1 544 limbs in the control arms (2.7% crude risk). The risk of major amputation was significantly higher for paclitaxel coated balloons with a hazard ratio (HR) of 1.66 (95% CI 1.14 - 2.42; p = .008, one stage stratified Cox model). The prediction interval was 95% CI 1.10 - 2.46 (two stage model). The observed amputation risk was consistent for both femoropopliteal (p = .055) and infrapopliteal (p = .055) vessels. Number needed to harm was 35 for CLI. There was good evidence of a significant non-linear dose response relationship with accelerated risk per cumulative paclitaxel dose (chi square model p = .007). There was no evidence of publication bias (p = .80) and no significant statistical heterogeneity between studies (I2 = 0%, p = .77). Results were stable across sensitivity analyses (different models and subgroups based on anatomy and clinical indication and excluding unpublished trials). There were no influential single trials. Level of certainty in evidence was downrated from high to moderate because of sparse events in some studies. There appears to be heightened risk of major amputation after use of paclitaxel coated balloons in the peripheral arteries. Further investigations are warranted urgently.

1 May 2009 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Francesco VersaciFrancesco Versaci
Francesco Versaci
BRBernhard Reimers
Bernhard Reimers
CGCostantino Del Giudice
Costantino Del Giudice
JSJoachim Schofer
Joachim Schofer
AGAlessandro Giacomin
Alessandro Giacomin
LCLuigi Chiariello
Luigi Chiariello

24 December 2015 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
GAGregory Amouyal
Gregory Amouyal
NTNicolas Thiounn
Nicolas Thiounn
OPOlivier Pellerin
Olivier Pellerin
LYLin Yen-Ting
Lin Yen-Ting
CGCostantino Del Giudice
Costantino Del Giudice
MSMarc Sapoval
Marc Sapoval